HDAC Inhibitor Mysteries Remain As Candidates Advance
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
With more than a dozen candidates in the clinic and a range of indications expanding outside oncology, the histone deacetylase inhibitor class could be poised to make major inroads. But much remains to be learned about the activity, and companies are scrambling to find biomarkers.